Gleolan and Orudis KT
Determining the interaction of Gleolan and Orudis KT and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid. MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid. References "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Professional:GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.
MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid.
- "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Generic Name: ketoprofen
Brand name: Oruvail, Orudis, Actron, Orudis KT
Synonyms: Orudis KT (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Gleolan-Oruvail
- Gleolan-Orvaten
- Gleolan-Os-Cal 500+D
- Gleolan-Os-Cal 500+Extra D Chewable
- Gleolan-Os-Cal Extra D3
- Gleolan-Oscimin (Hyoscyamine Orally Disintegrating Tablets)
- Orudis KT-Gleostine
- Orudis KT-Gliadel
- Orudis KT-Glimepiride
- Orudis KT-Glimepiride and pioglitazone
- Orudis KT-Glipizide
- Orudis KT-Glipizide and metformin